drugset
drugset / Trial / NCT00776295

Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

NCT00776295 ↗

Phase 2 Terminated 2 enrolled H. Lee Moffitt Cancer Center and Research Institute
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether p53 vaccination followed by high dose chemotherapy and autologous HCT and T cell therapy significantly induces immune responses resulting in 1-year survival greater that the current 70%.

Timeline

Start
2007-05
Primary completion
2010-06
Completion
2010-08

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject adenovirus vectored p53 tranfected dedritic cell vaccine Vaccine — —
Subject ex vivo expanded T-lymphocytes Cell therapy — —

Indications

small cell lung carcinoma